Cubist Systematic Strategies’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-64,550
| Closed | -$1.56M | – | 4610 |
|
|
2023
Q1 | $1.56M | Sell |
64,550
-164,859
| -72% | -$2.07M | 0.01% | 1840 |
|
|
2022
Q4 | $2.42M | Buy |
229,409
+131,483
| +134% | +$1.06M | 0.01% | 1688 |
|
|
2022
Q3 | $441K | Buy |
97,926
+2,326
| +2% | +$10.6K | ﹤0.01% | 3258 |
|
|
2022
Q2 | $382K | Buy |
95,600
+77,486
| +428% | +$367K | ﹤0.01% | 3268 |
|
|
2022
Q1 | $133K | Sell |
18,114
-728
| -4% | -$4.35K | ﹤0.01% | 3162 |
|
|
2021
Q4 | $106K | Buy |
18,842
+8
| +0% | +$51 | ﹤0.01% | 3191 |
|
|
2021
Q3 | $121K | Sell |
18,834
-5,399
| -22% | -$34.7K | ﹤0.01% | 2711 |
|
|
2021
Q2 | $204K | Sell |
24,233
-63,958
| -73% | -$516K | ﹤0.01% | 2554 |
|
|
2021
Q1 | $926K | Buy |
+88,191
| New | +$1.24M | 0.01% | 1585 |
|
|
2020
Q4 | – | Sell |
-19,726
| Closed | -$253K | – | 2766 |
|
|
2020
Q3 | $253K | Sell |
19,726
-33,990
| -63% | -$429K | ﹤0.01% | 2041 |
|
|
2020
Q2 | $758K | Buy |
53,716
+27,535
| +105% | +$348K | 0.01% | 1346 |
|
|
2020
Q1 | $241K | Buy |
+26,181
| New | +$337K | 0.01% | 1631 |
|
|
2019
Q2 | – | Sell |
-500
| Closed | -$1K | – | 2634 |
|
|
2019
Q1 | $1K | Sell |
500
-950
| -66% | -$2.23K | ﹤0.01% | 2213 |
|
|
2018
Q4 | $3K | Buy |
+1,450
| New | +$4.17K | ﹤0.01% | 2007 |
|
Other funds holding PRVB
Cubist Systematic Strategies's PRVB Position: Q2 2023 in Review
Cubist Systematic Strategies sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 64,550 shares — an estimated $1.56M sold.
Cubist Systematic Strategies first reported a position in PRVB in Q4 2018 and held it in 14 quarters. The position peaked at $2.42M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Cubist Systematic Strategies reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Cubist Systematic Strategies sold 64,550 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.56M.
- Cubist Systematic Strategies first reported a position in Provention Bio, Inc. Common Stock in Q4 2018 and held it in 14 quarters.
- Cubist Systematic Strategies's Provention Bio, Inc. Common Stock position peaked at $2.42M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.